Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.63 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.63 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.63 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378185 | 0.89 | ITGB3 (0.57) | ITGB1 | |
| SCHEMBL7378190 | 0.89 | ITGB3 (0.57) | ITGB1 | |
| SCHEMBL7377326 | 0.86 | ITGB1 (0.70) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7377320 | 0.86 | ITGB1 (0.70) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL18068487 | 0.86 | ITGB1 (0.58) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7376050 | 0.84 | ITGB3 (0.61) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7376058 | 0.84 | ITGB3 (0.61) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7382025 | 0.84 | ITGB1 (0.73) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7372895 | 0.84 | ITGB1 (0.73) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6563221 | 0.83 | ITGB1 (0.63) | ITGB1ITGA4ITGA2ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2023-01-12 | — | — | US | disclosed |
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2021-09-30 | — | — | US | disclosed |
| WO-2016145258-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | ITGB1 2547/4885ITGA4 2468/4885ITGA2 2581/4885 |
| US-20210300890-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | ITGB1 2547/4885ITGA4 2468/4885ITGA2 2581/4885 |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ITGB1 1/4885ITGA4 10/4885ITGA2 6/4885 |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, CPT1A, CES1 | ITGB1 2402/4885ITGA4 3227/4885ITGA2 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.